Kei Sato was looking for his next big challenge five years ago when it smacked him — and the world — in the face. The ...

Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors ...

SARS-CoV-2, the virus responsible for COVID-19, infects cells by binding its spike protein to angiotensin-converting enzyme 2 (ACE2) receptors.

Discovered in the state of Ceará, Brazil, the novel coronavirus shares similarities with the virus responsible for Middle ...

Frequent mutations of SARS-CoV-2 have reduced the effectiveness of vaccines, highlighting the need for mutation-resistant ...

Bispecific antibodies targeting multiple SARS-CoV-2 sites offer enhanced neutralization against emerging variants, advancing ...

The pandemic hit Manchester much like it did elsewhere in the country, and across the world - suddenly and shockingly, ...

(NYSE: EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, and Rocketvax Ltd, one of Switzerland’s next-generation vaccine ...

Emergent BioSolutions (EBS) and Rocketvax announced entry into an agreement for Emergent’s strategic financial investment into Swiss Rockets, ...

Dropping everything-or being forced to-for COVID-19 had widespread effects. On this fifth anniversary of the pandemic, three ...